Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells
- Luis A Aparicio†2,
- Raquel Castosa†1,
- Mar Haz-Conde1,
- Marta Rodríguez1,
- Moisés Blanco1,
- Manuel Valladares2 and
- Angélica Figueroa1Email author
© Aparicio et al.; licensee BioMed Central Ltd. 2014
Received: 10 February 2014
Accepted: 28 June 2014
Published: 10 July 2014
Vinflunine (VFL) is a microtubule-targeting drug that suppresses microtubule dynamics, showing anti-metastatic properties both in vitro and in living cancer cells. An increasing body of evidence underlines the influence of the microtubules dynamics on the cadherin-dependent cell-cell adhesions. E-cadherin is a marker of epithelial-to-mesenchymal transition (EMT) and a tumour suppressor; its reduced levels in carcinoma are associated with poor prognosis. In this report, we investigate the role of VFL on cell-cell adhesions in bladder epithelial tumour cells.
Human bladder epithelial tumour cell lines HT1376, 5637, SW780, T24 and UMUC3 were used to analyse cadherin-dependent cell-cell adhesions under VFL treatment. VFL effect on growth inhibition was measured by using a MTT colorimetric cell viability assay. Western blot, immunofluorescence and transmission electron microscopy analyses were performed to assess the roles of VFL effect on cell-cell adhesions, epithelial-to-mesenchymal markers and apoptosis. The role of the proteasome in controlling cell-cell adhesion was studied using the proteasome inhibitor MG132.
We show that VFL induces cell death in bladder cancer cells and activates epithelial differentiation of the remaining living cells, leading to an increase of E-cadherin-dependent cell-cell adhesion and a reduction of mesenchymal markers, such as N-cadherin or vimentin. Moreover, while E-cadherin is increased, the levels of Hakai, an E3 ubiquitin-ligase for E-cadherin, were significantly reduced in presence of VFL. In 5637, this reduction on Hakai expression was blocked by MG132 proteasome inhibitor, indicating that the proteasome pathway could be one of the molecular mechanisms involved in its degradation.
Our findings underscore a critical function for VFL in cell-cell adhesions of epithelial bladder tumour cells, suggesting a novel molecular mechanism by which VFL may impact upon EMT and metastasis.
KeywordsMicrotubule Cell-cell contacts E-cadherin Vinflunine Bladder cancer
Bladder cancer is a common malignancy affecting the genitourinary system that represents the fifth most common cancer in the world. Transitional cell carcinoma (TCC) represents 95% of these tumours . Most bladder cancers (70%-80%) present non-muscle invasive or superficial disease confined to the bladder mucosa (Ta) or lamina propria (T1), and the remaining (20%-30%) are muscle-invasive at the time of diagnosis (T2-T4) . Although both bladder cancers originate from urothelium in the urinary bladder (the epithelium that lines the urinary tract), they have different clinical characteristics. Muscle invasive TCC of the bladder is associated with a high frequency of metastasis, resulting in poor prognosis for patients . Therefore, an effective strategy for preventing the progression of bladder cancer is clearly needed.
Epithelial cells bind to each other, forming a strong adhesive cell layer with important barrier functions. Cell-cell contacts comprise different types of junctions, but adherens junctions are the major cell–cell junctions that mediate cell recognition, adhesion, morphogenesis, and tissue integrity. Adherens junctions are linked to the actin cytoskeleton, establishing molecular communication with other cell–cell junctions and cell–substratum adhesions, and are involved in the organization and movement of the cells within the epithelium and in the transmission of information to the interior of the cell. The most important mediators of cell-to-cell adhesion are the transmembrane proteins called cadherins. E- and N-cadherin were the first cadherins identified . E-cadherin is the prototype and best-characterized member of adherens junctions in mammalian epithelial cells. It contains an extracellular domain that forms homophilic interactions in a calcium-dependent manner and is responsible for cell-to-cell adhesions, and a cytoplasmic domain linked to the actin cytoskeleton through its interaction with several catenins [5, 6]. E-cadherin is regarded as a tumour suppressor and its loss is associated with poor prognosis in carcinoma.
E-cadherin is considered a hallmark of epithelial-to-mesenchymal transition (EMT). EMT is an early step during carcinoma metastasis characterized by the loss of epithelial morphology and the acquisition of mesenchymal and motile characteristics, resulting from the loss of apical-basal polarity, the loss of cell–cell contacts, and the reorganization of the actin cytoskeleton [7–9]. Numerous studies suggest that EMT is associated with cancer cell invasion, recurrence, progression and metastasis in various malignancies, including bladder cancer . However, the EMT is a reversible transitional process, as the cells can return to their epithelial phenotype: a process that is known as mesenchymal-to-epithelial transition . The loss of E-cadherin expression may also have a pivotal role in tumour progression characterized by increased mobility and invasiveness in bladder cancer [12–14]. Indeed, several studies on the prognostic role of E-cadherin in bladder cancer have shown that its aberrant expression is associated to tumour progression and poor prognosis . A key change that occurs during EMT is the "cadherin switch", in which the normal expression of E-cadherin is replaced by the abnormal expression of N- or P-cadherin [16, 17]. Another important marker frequently used in cells undergoing EMT during metastatic progression is vimentin. Vimentin is an intermediate filament protein that is also upregulated during EMT. Vimentin expression induces cell changes including mesenchymal cell shape, increased cell motility, and loss of adhesion in epithelial cells during EMT . Other studies have also suggested that transcriptional and posttranscriptional regulators are involved in the control of EMT [19, 20]. E-cadherin is also regulated at posttranslational level; Hakai was the first posttranslational regulator of E-cadherin stability [19, 21]. Hakai is a RING finger-type E3 ubiquitin-ligase for the E-cadherin complex that mediates E-cadherin ubiquitination, endocytosis and degradation; in consequence, it disrupts cell-cell contacts. Moreover, many articles have described the emerging biological functions for Hakai protein pointing out its influence on tumour progression during EMT, proliferation, and oncogenesis [21–28].
The microtubule system, a major component of the cytoskeleton, was identified as a suitable target for cancer therapy, primarily based on their biological importance in coordinating chromosome segregation during mitosis. Microtubules are macromolecular filaments composed of tubulin. The clinical efficacy of the first-generation vinka alkaloid has prompted further research for novel analogues with improved clinical efficacy and safety. Such efforts have led to the development of vinflunine (VFL), a third-generation, semi-synthetic vinca alkaloid that, similar to other microtubule-targeting drugs, suppresses microtubule dynamics both in vitro and in living cancer cells [29, 30]. In contrast to other vinca alkaloids, VFL shows superior antitumor activity and an excellent safety profile. VFL was approved by the European Medicines Agency (EMEA) as a second-line treatment for patients with urothelial carcinoma resistant to first-line platinum-containing chemotherapy [31, 32]. VFL has shown anti-angiogenic, anti-vascular and anti-metastatic properties in vitro and in vivo. Some potential underlying mechanisms of the anti-angiogenic property of microtubule targeting-agents have been reviewed [34, 35]. Interestingly, in endothelial cells, it was shown that microtubule-targeting agents, including VFL, may produce their anti-migratory/anti-angiogenic effects through an increase in interphase microtubule dynamics. In endothelial cells, at low and non-cytotoxic concentrations, VFL inhibits cell motility .
Although cadherins are best understood to cooperate with the actin cytoskeleton, there is increasing evidence supporting a role of the microtubules in regulating cadherin biology. Indeed, the cross-talk between microtubule networks and cell-cell adhesion sites profoundly impact upon these structures and is essential for proper cell organization, polarization and motility [37–42]. In the current study, we wanted investigate the possible impact of the microtubule-targeting drug VFL on E-cadherin-based cell-cell adhesion, and to determine the possible influence on the EMT transition markers in epithelial bladder tumour cell lines. We describe that VFL induces cell death in bladder cancer cells and activates epithelial differentiation of the remaining living cells. It has an impact on cell-cell contact, leading to an increase E-cadherin dependent cell-cell adhesion, while reducing vimentin and N-cadherin mesenchymal markers. Moreover, the levels of the E3 ubiquitin-ligase Hakai were significantly reduced by VFL treatment in all cell lines tested. Moreover, this reduction in Hakai protein levels was recovered in presence of the proteasome inhibitor MG132 in 5637 cell line, suggesting that Hakai could be, at least, partially degraded in a proteasome-dependent manner. Our data suggest that VFL may be involved in a cross-talk between microtubule networks and cell-cell adhesion sites by its function as a microtubule-targeting drug, suggesting a novel molecular mechanism by which VFL may impact upon EMT and metastasis.
Cell culture and treatments
Human bladder epithelial tumour cell lines HT1376, 5637, UMUC3, SW780 and T24 were used. HT1376 cell line was obtained from American Type Culture Collections (Manassas, VA). UMUC3 and SW780 were generously donated by Dr. F. Garcia (Pharmamar S.A., Madrid) and 5637 and T24 by Dr. F. Real (Spanish National Cancer Research Centre from Madrid, Spain). HT1376 and UMUC3 cells were cultured in DMEM medium (Gibco, LifeTech), 5637 was cultured in RPMI medium (Gibco, LifeTech), SW780 was cultured in Leibovitz’s medium (Gibco, LifeTech) and T24 cell line was culture in McCoy’s 5A (Gibco, LifeTech); each media was supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 1% L-glutamine and 10% foetal bovine serum. Cultures were maintained at 37ºC with 5% CO2 in a humidified incubator. HT1377 cells were grown in the indicated medium additionally supplemented with non-essential aminoacids (Gibco, LifeTech). A stock solution of vinflunine was prepared in distilled water. Cells were treated with VFL at the indicated final concentrations and for the times shown. MG132 was obtained from Sigma-Aldrich (St Louis, USA) and was added to the medium at final concentration of 20 μM for 2 hours.
Antibodies and reagents
Antibodies were used that recognized the cytoplasmic portion of E-cadherin (Invitrogen, California, USA), Hakai (Hakai-2498, kindly provided by Dr. Yasuyuki Fujita ), N-cadherin (Abcam, Cambridge, UK), vimentin (Cell Signaling Technology, Massachussetts, USA), cyclin D1 (Santa Cruz Biotechnology, Texas, USA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Invitrogen, California, USA). HRP-rabbit and mouse polyclonal antibodies were from GE Healthcare (Uppsala, Sweden) and Alexa Fluor 488 secondary antibody was from Invitrogen (UK). All antibodies were used at dilutions of 1:1000 for Western blot analysis, except for HRP-rabbit, mouse polyclonal antibodies, and anti-GAPDH antibodies that were used at 1:2000, 1:2000, and 1:10000 respectively. E-cadherin antibody (BD Bioscence, California, USA) was used for immunofluorescence at a dilution of 1:500 and Alexa Fluor 488 secondary antibody was used at a dilution of 1:100.
For cytotoxicity assays, 1 × 104 cells were plated per well into a 96-well plate and cultured for 24 h before treatment with VFL for 48 h. Serial dilutions of VFL dissolved in fresh medium were added to the cells in fresh medium. Growth inhibition of the epithelial tumour bladder cell lines was measured by using a MTT colorimetric cell viability assay kit (Sigma Aldrich, St Louis, MO) according to the manufacturer’s instructions. To measure absorbance at 570 nm, a Multiskan Plus Reader (Thermo Fisher, MA, USA) was used. The half-maximal inhibitory concentration (IC50) and the corresponding 95% confidence interval (95% CI) values were calculated from dose–response curves constructed using GraphPad Prism software. The data presented are the average of three independent experiments performed six times.
Phase contrast microscopy
For phase-contrast images, 2 × 105 cells were plated per well in a 6-well plate and treated with the indicated final concentrations of VFL (VFL) during 48 h. Cells were then fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min. Phase-contrast images were acquired using a Nikon Eclipse-Ti microscope.
Protein was isolated using TriPure Reagent (Roche, Germany) according to the manufacturer’s instructions. Cell lysates (20 μg of proteins) were obtained by lysing cells in a buffer containing 1% Triton X-100 (20 mM Tris/HCl pH 7.5, 150 mM NaCl and 1% Triton X-100), a protease inhibitor cocktail (Sigma Aldrich, St Louise, USA), and 50 mM PMSF. Western blot analysis was performed as described previously .
Transmission electron microscopy
For transmission electron microscopy, 5 × 104 cells of 5637 bladder tumour cell line were plated into 0.4 μm-pore culture inserts (Corning 353095, USA) placed on a 24-well plate. After treatment with 5 μM of VFL during 48 hours, cells were fixed with 2.5% cold glutaraldehyde (Panreac, Spain) in 0.1 M sodium cacodylate buffer (Sigma-Aldrich, Germany) pH 7.4, for 16 h at 4°C. Inserts were postfixed in 1% osmium tetroxide in 0.1 M sodium cacodylate buffer, pH 7.4, for 1 h at room temperature, following by several washes with 0.1 M sodium cacodylate buffer and distilled water. Inserts were dehydrated in increasing concentrations of acetone and embedded in Spurr’s resin (Taab, Berkshire, UK). Ultrathin sections of 70– to 80-nm thickness were cut using an Ultracut-E ultramicrotome (Leica) and collected on formvar-coated copper mesh grids. Samples were examined with a JEOL JEM 1010 transmission electron microscope at 80 kV.
Immunofluorescence and TUNEL assay
For immunofluorescence and TUNEL assay, 3 × 104 cells were plated in chambers slides (Millipores, USA), fixed in 4% paraformaldehyde for 10 min, and then permeabilized in 0.5% Triton X-100-phosphate buffered saline (PBS) for 15 min. Cell death was measured by using Click-it TUNEL Alexa Fluor® 594 Imaging Assay (Invitrogen, UK) according to manufacturer’s instructions followed by blocking with BSA 3% in PBS for 1 h. Incubation with E-cadherin primary antibody for 1 h was followed by incubation in Alexa-Fluor 488-conjugated secondary antibody solution for 1 h. To visualize nuclei, it was used 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI, LifeTech, UK).Finally, the mounting media used was ProLong Gold antifade reagent (LifeTech, USA). Epifluorescence images were taken in Olympus microscope.
Total RNA was isolated using TriPure Reagent (Roche, Germany) according to manufacturer´s instruction. The immunoprecipitated RNA pellet was washed by following an alternative protocol described for small RNAs in RiboPure (Life Technologies, UK). The quality and quantity of the obtained RNA was determined by using Nanodrop ND-spectrophotometer (Thermo Fisher Scientific, MA, USA). For reverse transcription (RT), random hexamers and SuperScript first-strand Synthesis System for RT-PCR (Invitrogen, UK) were used. For mRNA analysis, real-time quantitative (q)PCR analysis was performed using gene-specific primers 5’-CGCAGACGAATTCCTATAAAGC-3’ and 5’- CCTTCTTCATCACCAGGTGG -3’ for human Hakai and 5’-TGACCTTGATTTATTTTGCATACC-3’ and 5’-CGAGCAAGACGTTCAGTCCT-3’ for HPRT. PCR was performed by using Light Cycler 480 SYBR Green I Master (Roche, Germany); amplification and quantification were carried out using a LightCycler 480 real-time lightcycler (Roche, Germany).
Unless indicated, all experiments were analysed by using Students t-test to evaluate differences between treatments at the indicated significance levels.
Vinflunine induces epithelial phenotype in bladder tumour cells
VFL effect on epithelial-to-mesenchymal transition markers
VFL promotes proteasome-mediated Hakai degradation
The transitional cell carcinomas of the bladder that invade muscle are associated with high frequency of metastasis, which is the major cause of death from cancer. Microtubules, a major component of the cytoskeleton, are one of the best established targets for cancer therapy. Indeed, the microtubule-targeting drug VFL, which suppresses microtubule dynamics in vitro and in vivo, is the recommended option treatment of metastatic transitional cell carcinoma of the urothelial tract which has progressed after treatment with platinum-containing chemotherapy. Given the increasing body of evidence supporting that microtubules regulate cadherin biology, and the well-established role of E-cadherin in the EMT during bladder cancer progression and metastasis, here we have studied the effect of VFL on E-cadherin cell-cell adhesions. Using bladder cancer cell lines, we have shown that VFL treatment induces cell death in bladder cancer cells and activates epithelial differentiation in the remaining cells, leading to increased E-cadherin-dependent cell-cell adhesions and to reduced levels of mesenchymal markers, such as N-cadherin or vimentin. Moreover, we have demonstrated that Hakai, a post-translational regulator of E-cadherin stability, was significantly reduced in a VFL-dependent manner in 5637 suggesting that the proteasome pathway is at least partially involved in its diminution; however, other post-translational mechanisms are waiting to be investigated. In conclusion, we have demonstrated a novel molecular mechanism of VFL to explain its anti-invasive effect.
In the last few years, differentiation therapy came out as a novel strategy for treating cancers. This approach is based on the concept that cancer cells arise from tissue stem cells and share the stemness and plasticity with normal stem cells. Differentiation therapy aims to induce cancer cells to differentiate by treatment with differentiation-inducing agents [46, 47]. Most of the differentiation agents can inhibit proliferation and induce cells to differentiate and then undergo apoptosis [48, 49]. It is well established that VFL blocks mitosis at the metaphase/anaphase transition, leading to apoptosis . It is still necessary to elucidate how VFL could modulate epithelial cell differentiation and cell death; however, it appears to be an important therapeutic strategy for transitional cell carcinomas by its influence on these processes. Understanding the differentiation mechanisms and the fate of the treated cells may eventually lead us to gain insights into cancer therapy by differentiation.
Cadherins are key mediators of cell-to-cell adhesion in epithelial tissues. The roles of these proteins in bladder cancer-related EMT have been investigated extensively. Bryan and Tselepis summarized the patterns of P-cadherin and N-cadherin expression in the bladder during EMT . In the normal urothelium, P-cadherin, but not N-cadherin, is expressed in the basal layer. However, during the EMT, P-cadherin expression in bladder cancer cells is upregulated along with N-cadherin expression; these events occur either independently or synchronously. E-cadherin expression in bladder cancer cells is lost after changes in P- and/or N-cadherin expression levels, as invasion and metastasis increase. This cadherin switching event is an important process that occurs late in the molecular pathogenesis of bladder cancer; although the precise timing and nature of these events remain unknown. On the other hand, the mesenchymal intermediate filament, vimentin, often increases its expression in carcinoma cells that have undergone an EMT. However, under VFL treatment, vimentin downregulation is observed in UMUC3 cell line but not in 5637. Vimentin levels are not always affected during the reversion of mesenchymal-to-epithelial transition. Indeed, partial EMT has been suggested to occur in some metastatic cancers, where distant metastasis can retain much of the epithelial differentiation of the original tissue of the cancer . For instance, under silibinin treatment, a natural agent that reverses EMT, vimentin mesenchymal marker was not always influenced by this agent. Indeed, it was observed that vimentin was not always regulated by silibinin during MET and this modulation was dependent on the type of prostate epithelial tumor cells [53, 54]. Various lines of evidence clearly indicate that the EMT is strongly associated with aggressive bladder cancer behavior, such as recurrence, progression, and metastasis, an observation that raises the possibility that the EMT may be a target for bladder cancer treatment. As mentioned above, E-cadherin is the first and most important regulator of the EMT. Moreover, in bladder cancer, loss of E-cadherin expression is a marker of poor response to the monoclonal antibody cetuximab, which blocks EGFR binding and represses bladder cancer cell proliferation . Thus, E-cadherin expression levels could constitute an important predictive marker for the responsiveness to microtubule-targeting VFL therapy.
Several studies have demonstrated the influence of the microtubules on cadherin-dependent cell-cell adhesions. Kitase et. al. demonstrated that RhoA is implicated during neurodetermination, where it influences cell-cell contact and cadherin levels . They used the P19 cell model of neuronal differentiation to show that RhoA affects cadherin protein level and cell-cell contacts during neuroinduction. RhoGTPases have an important role during neurite growth, axonal guidance, and synaptogenesis [57–59]. The cellular effects of RhoA are mediated by ROCK and seem to involve microtubules, pointing, for the first time, at the existence of a potential complex cross-talk between RhoA/ROCK, N-cadherin, and microtubules. The effect on cadherin level occurred in the timing that corresponds to the switch of E- to N-cadherin that trigger neurodifferentiation . N-cadherin level appears to be critical for cell fate determination during morphogenesis. Advanced induction of Cdc42 had similar effects to RhoA inactivation, underscoring the importance of correct timing of RhoGTPases during neurodifferentiation .
Similar to VFL, another microtubule destabilizing agent, nocodazole, influenced cell-cell adhesions. The study reporting these findings examined the role of microtubules on the transcriptional regulation of cell adhesion proteins, providing evidence that the microtubule cytoskeleton critically affects EMT by regulating TGF-β/SMAD2 signaling during palatal fusion and prevents E-cadherin repression . During palatal fusion, the midline epithelial seam (MES) degrades to achieve mesenchymal confluence. EMT is one of the mechanisms that function during MES degradation. TGF-β induces EMT in medial edge epithelium (MEE) by down-regulating the epithelial marker E-cadherin. Microtubule disassembly impaired palatal fusion leading to a multi-layered MES in the mid-region and inhibited palatal fusion accompanied by the development of a multi-layered MES in the mid-palatal region . The authors further showed that treatment with nocodazole led to the accumulation of cell-cell adhesion proteins at intercellular junctions in medial edge epithelium . Microtubule disruption by nocodazole triggered the aberrant accumulation of E-cadherin adhesion at intercellular junctions in MEE. Due to the aberrant expression of both negative (Snail and Zeb) and positive (c-MYC) E-cadherin transcriptional regulators when the TGF-β/SMAD2 signaling pathway was blocked, resulted in failure for EMT to progress. These data also support the important role of the microtubule cytoskeleton in mediating TGF-β/SMAD2 signals to control E-cadherin expression in MEE during palatal fusion .
Several lines of evidence support that the interaction of the microtubules with cadherin affects cadherin biology . First, the junctional integrity of cadherin is perturbed by drugs such as nocodazole and VFL, which disrupt microtubules. Second, specific targeting of microtubule-binding proteins found at junctions also impairs broad aspects of cadherin biology. For example, Nezha-bound microtubules at their minus ends and tethered them to the zonula adherens. In cultured mammalian epithelial cells, depletion of either Nezha or PLEKHA7, which is responsible for recruiting Nezha to p120-ctn, disrupted the ability of cells to concentrate E-cadherin to the apical junction of the zonula adherens. The functional impact of these junctional microtubule-binding proteins further supports the idea that microtubules that interact with cadherin adhesions are responsible for regulating junctional integrity. Still, how microtubules influence these diverse aspects of cadherin biology is complex and poorly understood. Microtubules are commonly implicated in directing intracellular traffic of membrane-bound vesicles or molecular complexes; accordingly, it was postulated to influence cadherins through their intracellular traffic. Indeed, a number of microtubule-based motors have been identified that support intracellular transport of cadherins .
The EMT is regarded as a key process that allows cancer cells to migrate to adjacent organs or metastasize to distant sites. In bladder cancer, EMT is closely associated with grave clinical characteristics, such as recurrence, progression, metastasis, and reduced survival. However, metastases of the most common human cancers (well- to moderately-differentiated carcinomas) often show a re-differentiation in the sense of a mesenchymal-epithelial transition (MET). Therefore, strategies to induce reversal EMT (MET), such as VFL, might be able to suppress cancer cell migration and metastasis. However, this issue is controversial, as several lines of evidence support that transient dedifferentiation (EMT) and re-differentiation (MET) processes are a driving force in metastasis . Although many clinical reports fostered the concept of transient EMT-MET switches in metastasis, only little experimental evidence is available . Chaffer et al. support the role of an EMT in dissemination and the need of a MET for efficient metastasis in bladder cancer metastasis . Two reports support the need of re-differentiation (MET) for the colonization and metastasis of differentiated carcinomas and implicate EMT-associated growth arrest in these events [67–69]. Therefore, MET has a key clinical impact for future therapeutic strategies against metastasis. On one hand, EMT-targeting therapy may be useful as a personalized medicine approach that complements conventional bladder cancer treatments, while on the other hand, the induction of differentiation and targeting EMT alone might be counterproductive by activating the proliferation of disseminated cells. It is possible that therapeutic approaches directed against EMT can benefit cancer patients diagnosed at early stages of the disease to prevent invasion and dissemination, while anti-MET drugs could be potentially benefit patients with established metastasis. Still, a better understanding of the molecular mechanisms of the EMT in bladder cancer is crucial to the development of new therapeutic modalities for this cancer [69, 70].
Our data suggest that VFL, a microtubule-targeting drug, may be involved in a cross-talk between microtubule networks and cell-cell adhesions. We suggest a novel molecular mechanism by which VFL may impact upon EMT and metastasis. VFL impacts on E-cadherin-based cell-cell adhesion and influence on the EMT markers in epithelial bladder tumour cell lines. We have shown that VFL induces cell death in bladder cancer cells and activates epithelial differentiation of the remaining living cells. VFL increases E-cadherin dependent cell-cell adhesion, and reduces vimentin and N-cadherin mesenchymal markers. Moreover, the levels of the E3 ubiquitin-ligase Hakai were reduced by VFL in 5637 suggesting that proteasome-dependent mechanism could be one of the molecular mechanisms implicated in this reduction. Our findings suggest the existence of a new mechanism of VFL-microtubule targeting drug to cell-cell contacts with potential functional implications in the maintenance of epithelial cell phenotype.
Medial edge epithelium
Transitional cell carcinoma
This work is supported by grants from Consellería de Sanidade (PS09/24), from Secretaría Xeral I + D + I, (10CSA916023PR), both from Xunta de Galicia; and from Instituto Carlos III (Acción Estratégica de Salud 2013–2016, PI13/00250). R.C. is the recipient of a grant from Secretaria Xeral I + D + I (10CSA916023PR), Xunta de Galicia. A.F was supported by Secretaria Xeral I + D + I (IPP.08-07), from Xunta de Galicia. Part of this work was awarded in the XIX edition of the “Rafael Hervada” from San Rafael Hospital (A Coruña, Spain).
- Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29.View ArticlePubMedGoogle Scholar
- Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP: Biology and management of bladder cancer. N Engl J Med. 1990, 322 (16): 1129-1138.View ArticlePubMedGoogle Scholar
- Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009, 55 (4): 815-825.View ArticlePubMedGoogle Scholar
- Nollet F, Kools P, van Roy F: Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol. 2000, 299 (3): 551-572.View ArticlePubMedGoogle Scholar
- Perez-Moreno M, Jamora C, Fuchs E: Sticky business: orchestrating cellular signals at adherens junctions. Cell. 2003, 112 (4): 535-548.View ArticlePubMedGoogle Scholar
- Yonemura S: Cadherin-actin interactions at adherens junctions. Curr Opin Cell Biol. 2011, 23 (5): 515-522.View ArticlePubMedGoogle Scholar
- Christofori G: New signals from the invasive front. Nature. 2006, 441 (7092): 444-450.View ArticlePubMedGoogle Scholar
- Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008, 14 (6): 818-829.View ArticlePubMedGoogle Scholar
- Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139 (5): 871-890.View ArticlePubMedGoogle Scholar
- Yun SJ, Kim WJ: Role of the Epithelial-Mesenchymal Transition in Bladder Cancer: From Prognosis to Therapeutic Target. Korean J Urol. 2013, 54 (10): 645-650.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen J, Han Q, Pei D: EMT and MET as paradigms for cell fate switching. J Mol Cell Biol. 2012, 4 (2): 66-69.View ArticlePubMedGoogle Scholar
- Birchmeier W, Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994, 1198 (1): 11-26.PubMedGoogle Scholar
- Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W: Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol. 1993, 120 (3): 757-766.View ArticlePubMedGoogle Scholar
- Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998, 392 (6672): 190-193.View ArticlePubMedGoogle Scholar
- Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K, Debruyne FM, Bringuier PP: Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res. 1996, 56 (18): 4154-4158.PubMedGoogle Scholar
- De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, Gespach C, Bracke M, Berx G: Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol. 2008, 130 (3): 481-494.View ArticlePubMedPubMed CentralGoogle Scholar
- Yilmaz M, Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28 (1–2): 15-33.View ArticlePubMedGoogle Scholar
- Mendez MG, Kojima S, Goldman RD: Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010, 24 (6): 1838-1851.View ArticlePubMedPubMed CentralGoogle Scholar
- Aparicio LA, Valladares M, Blanco M, Alonso G, Figueroa A: Biological influence of Hakai in cancer: a 10-year review. Cancer Metastasis Rev. 2012, 31 (1-2): 375-386.View ArticlePubMedPubMed CentralGoogle Scholar
- Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, García De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000, 2 (2): 84-89.View ArticlePubMedGoogle Scholar
- Fujita Y, Krause G, Scheffner M, Zechner D, Leddy H, Behrens J, Sommer T, Birchmeier W: Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol. 2002, 4 (3): 222-231.View ArticlePubMedGoogle Scholar
- Swaminathan G, Cartwright CA: Rack1 promotes epithelial cell-cell adhesion by regulating E-cadherin endocytosis. Oncogene. 2011, 31 (3): 376-389.View ArticlePubMedGoogle Scholar
- Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M: Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene. 2006, 25 (54): 7117-7130.View ArticlePubMedGoogle Scholar
- Zhou WJ, Geng ZH, Chi S, Zhang W, Niu XF, Lan SJ, Ma L, Yang X, Wang LJ, Ding YQ, Geng JG: Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis. Cell Res. 2011, 21 (4): 609-626.View ArticlePubMedPubMed CentralGoogle Scholar
- Figueroa A, Kotani H, Toda Y, Mazan-Mamczarz K, Mueller E, Otto A, Disch L, Norman M, Ramdasi R, Keshtgar M, Gorospe M, Fujita Y: Novel roles of hakai in cell proliferation and oncogenesis. Mol Biol Cell. 2009, 20 (15): 3533-3542.View ArticlePubMedPubMed CentralGoogle Scholar
- Figueroa A, Fujita Y, Gorospe M: Hacking RNA: Hakai promotes tumorigenesis by enhancing the RNA-binding function of PSF. Cell Cycle. 2009, 8 (22): 3648-3651.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodríguez-Rigueiro T, Valladares-Ayerbes M, Haz-Conde M, Aparicio LA, Figueroa A: Hakai reduces cell-substratum adhesion and increases epithelial cell invasion. BMC Cancer. 2011, 11: 474-View ArticlePubMedPubMed CentralGoogle Scholar
- Abella V, Valladares M, Rodriguez T, Haz M, Blanco M, Tarrío N, Iglesias P, Aparicio LA, Figueroa A: miR-203 Regulates Cell Proliferation through Its Influence on Hakai Expression. PLoS One. 2012, 7 (12): e52568-View ArticlePubMedPubMed CentralGoogle Scholar
- Jordan MA, Horwitz SB, Lobert S, Correia JJ: Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin Oncol. 2008, 35 (3 Suppl 3): S6-S12.View ArticlePubMedGoogle Scholar
- Jordan MA, Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004, 4 (4): 253-265.View ArticlePubMedGoogle Scholar
- Gerullis H, Ecke T, Eimer C, Wishahi M, Otto T: Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review. Anticancer Drugs. 2011, 22 (1): 9-17.View ArticlePubMedGoogle Scholar
- Gerullis H: Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy. Drugs Today (Barc). 2011, 47 (1): 17-25.View ArticleGoogle Scholar
- Aparicio LM, Pulido EG, Gallego GA: Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs. 2012, 23 (1): 1-11.View ArticlePubMedGoogle Scholar
- Pasquier E, Honoré S, Braguer D: Microtubule-targeting agents in angiogenesis: where do we stand?. Drug Resist Updat. 2006, 9 (1–2): 74-86.View ArticlePubMedGoogle Scholar
- Schwartz EL: Antivascular actions of microtubule-binding drugs. Clin Cancer Res. 2009, 15 (8): 2594-2601.View ArticlePubMedPubMed CentralGoogle Scholar
- Honoré S, Pagano A, Gauthier G, Bourgarel-Rey V, Verdier-Pinard P, Civiletti K, Kruczynski A, Braguer D: Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites. Mol Cancer Ther. 2008, 7 (7): 2080-2089.View ArticlePubMedGoogle Scholar
- Akhmanova A, Yap AS: Organizing junctions at the cell-cell interface. Cell. 2008, 135 (5): 791-793.View ArticlePubMedGoogle Scholar
- Akhmanova A, Stehbens SJ, Yap AS: Touch, grasp, deliver and control: functional cross-talk between microtubules and cell adhesions. Traffic. 2009, 10 (3): 268-274.View ArticlePubMedGoogle Scholar
- Stehbens SJ, Paterson AD, Crampton MS, Shewan AM, Ferguson C, Akhmanova A, Parton RG, Yap AS: Dynamic microtubules regulate the local concentration of E-cadherin at cell-cell contacts. J Cell Sci. 2006, 119 (Pt 9): 1801-1811.View ArticlePubMedGoogle Scholar
- Stehbens SJ, Akhmanova A, Yap AS: Microtubules and cadherins: a neglected partnership. Front Biosci (Landmark Ed). 2009, 14: 3159-3167.View ArticleGoogle Scholar
- Han SP, Yap AS: The cytoskeleton and classical cadherin adhesions. Subcell Biochem. 2012, 60: 111-135.View ArticlePubMedGoogle Scholar
- Shtutman M, Chausovsky A, Prager-Khoutorsky M, Schiefermeier N, Boguslavsky S, Kam Z, Fuchs E, Geiger B, Borisy GG, Bershadsky AD: Signaling function of alpha-catenin in microtubule regulation. Cell Cycle. 2008, 7 (15): 2377-2383.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodríguez Rigueiro T, Valladares Ayerbes M, Haz Conde M, Blanco M, Aparicio G, Fernández Puente P, Blanco FJ, Lorenzo MJ, Aparicio LA, Figueroa A: A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues. Proteomics. 2011, 11 (12): 2555-2559.View ArticlePubMedGoogle Scholar
- Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincenti M: Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol. 2002, 7 (4): 159-166.View ArticlePubMedGoogle Scholar
- Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994, 78 (5): 761-771.View ArticlePubMedGoogle Scholar
- Zhang Z, Zhou Y, Qian H, Shao G, Lu X, Chen Q, Sun X, Chen D, Yin R, Zhu H, Shao Q, Xu W: Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death Dis. 2013, 4: e633-View ArticlePubMedPubMed CentralGoogle Scholar
- Guichet PO, Bieche I, Teigell M, Serguera C, Rothhut B, Rigau V, Scamps F, Ripoll C, Vacher S, Taviaux S, Chevassus H, Duffau H, Mallet J, Susini A, Joubert D, Bauchet L, Hugnot JP: Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors. Glia. 2013, 61 (2): 225-239.View ArticlePubMedGoogle Scholar
- Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, Combs SE, Goidts V, Helmke BM, Eckstein V, Roth W, Beckhove P, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende C: Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res. 2010, 16 (10): 2715-2728.View ArticlePubMedGoogle Scholar
- Seigel GM: Differentiation potential of human retinoblastoma cells. Curr Pharm Biotechnol. 2011, 12 (2): 213-216.View ArticlePubMedGoogle Scholar
- Okouneva T, Hill BT, Wilson L, Jordan MA: The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther. 2003, 2 (5): 427-436.PubMedGoogle Scholar
- Bryan RT, Tselepis C: Cadherin switching and bladder cancer. J Urol. 2010, 184 (2): 423-431.View ArticlePubMedGoogle Scholar
- Debnath J, Brugge JS: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 2005, 5 (9): 675-688.View ArticlePubMedGoogle Scholar
- Deep G, Gangar S, Agarwal C, Agarwal R: Role of E-cadherin in anti-migratory and anti-invasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila). 2011, 4 (8): 1222-1232.View ArticleGoogle Scholar
- Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y, Zhu G, Yang L, Wang X, He D: Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol Rep. 2010, 23 (6): 1545-1552.View ArticlePubMedGoogle Scholar
- Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008, 14 (5): 1478-1486.View ArticlePubMedGoogle Scholar
- Laplante I, Béliveau R, Paquin J: RhoA/ROCK and Cdc42 regulate cell-cell contact and N-cadherin protein level during neurodetermination of P19 embryonal stem cells. J Neurobiol. 2004, 60 (3): 289-307.View ArticlePubMedGoogle Scholar
- Lehmann M, Fournier A, Selles-Navarro I, Dergham P, Sebok A, Leclerc N, Tigyi G, McKerracher L: Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci. 1999, 19 (17): 7537-7547.PubMedGoogle Scholar
- Luo L: Rho GTPases in neuronal morphogenesis. Nat Rev Neurosci. 2000, 1 (3): 173-180.View ArticlePubMedGoogle Scholar
- Yuan XB, Jin M, Xu X, Song YQ, Wu CP, Poo MM, Duan S: Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat Cell Biol. 2003, 5 (1): 38-45.View ArticlePubMedGoogle Scholar
- Gao X, Bian W, Yang J, Tang K, Kitani H, Atsumi T, Jing N: A role of N-cadherin in neuronal differentiation of embryonic carcinoma P19 cells. Biochem Biophys Res Commun. 2001, 284 (5): 1098-1103.View ArticlePubMedGoogle Scholar
- Kitase Y, Shuler CF: Microtubule disassembly prevents palatal fusion and alters regulation of the E-cadherin/catenin complex. Int J Dev Biol. 2013, 57 (1): 55-60.View ArticlePubMedGoogle Scholar
- Kitase Y, Shuler CF: Multi-layered hypertrophied MEE formation by microtubule disruption via GEF-H1/RhoA/ROCK signaling pathway. Dev Dyn. 2012, 241 (7): 1169-1182.View ArticlePubMedGoogle Scholar
- Brieher WM, Yap AS: Cadherin junctions and their cytoskeleton(s). Curr Opin Cell Biol. 2013, 25 (1): 39-46.View ArticlePubMedGoogle Scholar
- Meng W, Mushika Y, Ichii T, Takeichi M: Anchorage of microtubule minus ends to adherens junctions regulates epithelial cell-cell contacts. Cell. 2008, 135 (5): 948-959.View ArticlePubMedGoogle Scholar
- Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001, 98 (18): 10356-10361.View ArticlePubMedPubMed CentralGoogle Scholar
- Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED: Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006, 66 (23): 11271-11278.View ArticlePubMedGoogle Scholar
- Ocaña OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA: Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012, 22 (6): 709-724.View ArticlePubMedGoogle Scholar
- Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J: Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell. 2012, 22 (6): 725-736.View ArticlePubMedPubMed CentralGoogle Scholar
- Brabletz T: EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell. 2012, 22 (6): 699-701.View ArticlePubMedGoogle Scholar
- Nieto MA, Cano A: The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol. 2012, 22 (5–6): 361-368.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/507/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.